Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study

NCT04166565 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT04166565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2019
Completion date
March 31, 2027
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

extramedullary plasmacytoma, multiple myeloma